Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.
Manish A ShahDavid CunninghamJean-Philippe MetgesEric Van CutsemZev WainbergEmon ElboudwarejKai-Wen LinScott TurnerMarianna ZavodovskayaDavid InzunzaJinfeng LiuScott D PattersonJingzhu ZhouJing HeDung ThaiPankaj BhargavaCarrie Baker BrachmannDaniel V T CantenacciPublished in: Journal for immunotherapy of cancer (2022)
NCT02864381 or GS-US-296--2013.